Few documents shape European dealmaking as quietly as the Commission’s merger guidelines, and for the first time in roughly two decades those rules are being torn up and rebuilt. On 30 April the competition directorate published a draft set of Merger Assessment Guidelines and opened them to public comment until 26 June, with a final text expected in the last quarter of the year. The exercise consolidates the horizontal guidance from 2004 and the non-horizontal guidance from 2008 into a single framework, but the housekeeping language understates what is really happening: the criteria that decide whether a deal lives or dies are being rewritten around innovation.
The old playbook judged mergers mostly by price and market share. A regulator asked whether combining two firms would let the survivor raise prices or squeeze rivals, and if the overlap looked modest the deal usually cleared. The draft keeps that logic but bolts on a series of new theories of harm built for industries where the decisive contest is over future products rather than current ones. Officials now want the power to block or condition a deal because it would shut down overlapping research pipelines, slow the overall pace of innovation in a sector, or remove a planned investment that had been disciplining incumbents. Tellingly, the text also names the entrenchment of platform ecosystems, portfolio effects, structural shareholdings between competitors, and even coordination assisted by artificial intelligence as live concerns.
The phrase doing the heaviest lifting is killer acquisitions, the practice of a dominant firm buying a promising young rival not to grow but to bury a threat before it matures. Antitrust enforcers have worried about these deals for years, particularly in pharmaceuticals and software, yet they often fell below the turnover thresholds that trigger review or looked harmless on a static market map. By writing the concept explicitly into the guidelines, the Commission signals that it will scrutinise the strategic logic of a purchase, not just the revenue it adds.
That tougher posture comes wrapped in a notable concession. The draft promises an innovation shield, under which the Commission will in principle not find a competition problem when a buyer acquires a small innovative company or an early-stage research project with genuine dynamic potential. The aim is to reassure venture investors and founders that the bloc still wants start-ups to be fundable and sellable, even as it hunts for the handful of acquisitions designed to smother competition. Whether those two instincts can coexist is the question that will dominate the consultation, because the line between nurturing a start-up and neutralising a future rival is rarely obvious at the moment a deal is signed.
For companies and their advisers the practical stakes are immediate. A framework that gives greater weight to claimed efficiencies and innovation benefits hands merging parties fresh arguments to justify a tie-up, yet the same text arms case teams with new grounds to demand remedies or open in-depth probes. Legal opinions circulating in the city this spring read the draft both ways, as a liberalisation for those who can document genuine synergies and as an expansion of discretion for an institution that has grown more willing to intervene.
What emerges in the autumn will set the terms for European consolidation across technology, defence, energy and pharmaceuticals at a moment when the bloc is also urging its champions to scale up and compete globally. The tension between encouraging size and policing it runs straight through this draft, and the comments arriving before 26 June will determine which instinct prevails.
